Pharmacotherapy of Child and Adolescent Depression

Child and Adolescent Psychiatric Clinics of North America

Volumn 15, Issue 4, 2006, Pages 977-998

  Moreno, Carmen ^a   Roche, Ansley M ^a   Greenhill, Laurence L ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ADOLESCENT DISEASE; AGITATION; ANOREXIA; ATTENTION DISTURBANCE; BACKACHE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BRAIN DEVELOPMENT; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; COUGHING; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPEPSIA; EUPHORIA; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HIPPOCAMPUS; HOSTILITY; HUMAN; HYPOMANIA; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; META ANALYSIS; NAUSEA; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; PHARYNGITIS; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; RHINITIS; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TERATOGENESIS; TREMOR; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; PAROXETINE; SERTRALINE; SOCIAL BEHAVIOR;

EID: 33748120333     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2006.05.006     Document Type: Review

References (103)

1. Costello E.J., Mustillo S., Erkanli A., et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60 8 (2003) 837-844
2. Hasin D.S., Goodwin R.D., Stinson F.S., et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 62 10 (2005) 1097-1106
3. Substance Abuse and Mental Health Services Administration. Youth violence and illicit drug use. Available at: http://oas.samhsa.gov/2k6/youthViolence/youthViolence.htm. Accessed February 7, 2006.
4. Lewinsohn P.M., Rohde P., and Seeley J.R. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev 18 7 (1998) 765-794
5. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 51 1 (1994) 8-19
6. Fleming J.E., and Offord D.R. Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 29 4 (1990) 571-580
7. Rao U., Weissman M.M., Martin J.A., et al. Childhood depression and risk of suicide: a preliminary report of a longitudinal study. J Am Acad Child Adolesc Psychiatry 32 1 (1993) 21-27
8. Weissman M.M., Wolk S., Goldstein R.B., et al. Depressed adolescents grown up. JAMA 281 18 (1999) 1707-1713
9. Birmaher B., Ryan N.D., Williamson D.E., et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 35 11 (1996) 1427-1439
10. Ma J., Lee K.V., and Stafford R.S. Depression treatment during outpatient visits by US children and adolescents. J Adolesc Health 37 6 (2005) 434-442
11. Wu P., Hoven C.W., Bird H.R., et al. Depressive and disruptive disorders and mental health service utilization in children and adolescents. J Am Acad Child Adolesc Psychiatry 38 9 (1999) 1081-1090 [discussion: 1090-2]
12. Pearce J.B. The recognition of depressive disorder in children. J R Soc Med 71 7 (1978) 494-500
13. Hughes C.W., Preskorn S.H., Weller E., et al. The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacol Bull 26 2 (1990) 235-238
14. Petti T.A., and Law III W. Imipramine treatment of depressed children: a double-blind pilot study. J Clin Psychopharmacol 2 2 (1982) 107-110
15. Preskorn S.H., Weller E.B., Hughes C.W., et al. Depression in prepubertal children: dexamethasone nonsuppression predicts differential response to imipramine vs. placebo. Psychopharmacol Bull 23 1 (1987) 128-133
16. Puig-Antich J., Perel J.M., Lupatkin W., et al. Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 44 1 (1987) 81-89
17. Kashani J.H., Shekim W.O., and Reid J.C. Amitriptyline in children with major depressive disorder: a double-blind crossover pilot study. J Am Acad Child Psychiatry 23 3 (1984) 348-351
18. Kramer A.D., and Feiguine R.J. Clinical effects of amitriptyline in adolescent depression: a pilot study. J Am Acad Child Psychiatry 20 3 (1981) 636-644
19. Geller B., Cooper T.B., Graham D.L., et al. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. Psychopharmacol Bull 26 1 (1990) 85-90
20. Geller B., Cooper T.B., McCombs H.G., et al. Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. Psychopharmacol Bull 25 1 (1989) 101-108
21. Birmaher B., Waterman G.S., Ryan N.D., et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. J Am Acad Child Adolesc Psychiatry 37 5 (1998) 527-535
22. Kye C.H., Waterman G.S., Ryan N.D., et al. A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. J Am Acad Child Adolesc Psychiatry 35 9 (1996) 1139-1144
23. Klein R.G., Mannuzza S., Koplewicz H.S., et al. Adolescent depression: controlled desipramine treatment and atypical features. Depress Anxiety 7 1 (1998) 15-31
24. Kutcher S., Boulos C., Ward B., et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 33 5 (1994) 686-694
25. Sallee F.R., Vrindavanam N.S., Deas-Nesmith D., et al. Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response. Biol Psychiatry 44 7 (1998) 562-567
26. Emslie G.J., Rush A.J., Weinberg W.A., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54 11 (1997) 1031-1037
27. Simeon J.G., Dinicola V.F., Ferguson H.B., et al. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 14 5 (1990) 791-795
28. Emslie G.J., Heiligenstein J.H., Wagner K.D., et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41 10 (2002) 1205-1215
29. March J., Silva S., Petrycki S., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292 7 (2004) 807-820
30. Keller M.B., Ryan N.D., Strober M., et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40 7 (2001) 762-772
31. Wagner K.D., Ambrosini P., Rynn M., et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290 8 (2003) 1033-1041
32. Wagner K.D., Robb A.S., Findling R.L., et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161 6 (2004) 1079-1083
33. Mandoki M.W., Tapia M.R., Tapia M.A., et al. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33 1 (1997) 149-154
34. Ryan N.D. Treatment of depression in children and adolescents. Lancet 366 9489 (2005) 933-940
35. Emslie G.J., Ryan N.D., and Wagner K.D. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. J Clin Psychiatry 66 Suppl 7 (2005) 14-20
36. Courtney D.B. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 49 8 (2004) 557-563
37. Pirraglia P.A., Stafford R.S., and Singer D.E. Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiatry 5 4 (2003) 153-157
38. Murray M.L., de Vries C.S., and Wong I.C. A drug utilisation study of antidepressants in children and adolescents using the general practice research database. Arch Dis Child 89 12 (2004) 1098-1102
39. Zito J.M., Safer D.J., DosReis S., et al. Rising prevalence of antidepressants among US youths. Pediatrics 109 5 (2002) 721-727
40. Medicines and Healthcare Products Regulatory Agency. Selective serotonin reuptake inhibitors: use in children and adolescents with major depressive disorder: Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019492.pdf. Accessed February 7, 2006.
41. US Food and Drug Administration. Labeling change request letter. Available at: http://www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm. Accessed February 7, 2006.
42. Murray M.L., Thompson M., Santosh P.J., et al. Effects of the committee on safety of medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 28 12 (2005) 1151-1157
43. Rosack J. New data show declines in antidepressant prescribing. Psychiatr News 40 17 (2005) 1
44. Barbui C., and Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 178 (2001) 129-144
45. Hazell P., O'Connell D., Heathcote D., et al. Tricyclic drugs for depression in children and adolescents (Cochrane review). The Cochrane Library (2004), John Wiley and Sons, Chichester
46. Milin R., Simeon J., and Spenst W. Double-blind study of paroxetine in adolescents with unipolar major depression (NR-67) (1999), American Academy of Child and Adolescent Psychiatry, Los Angeles (CA)
47. Cheung A.H., Emslie G.J., and Mayes T.L. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 46 7 (2005) 735-754
48. Mann J.J., Emslie G., Baldessarini R.J., et al. ACNP task force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 23 (2005) 473-492
49. GlaxoSmithKline. Current issues: paroxetine and pediatric and adolescent patients (Study #377). Available at: http://www.gsk.com/media/paroxetine.htm. Accessed February 7, 2006.
50. GlaxoSmithKline. Current issues: paroxetine and pediatric and adolescent patients (Study #701). Available at: http://www.gsk.com/media/paroxetine.htm. Accessed February 7, 2006.
51. Emslie GJ, Wagner K, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC; October 19-24, 2004.
52. Medicines and Healthcare Products Regulatory Agency. Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data: Available at: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&ssTargetNodeId=221&useSecondary=true&ssDocName=CON019494&showpage=2. Accessed February 7, 2006.
53. Wagner K.D., Jonas J., Findling R.L., et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45 3 (2006) 280-288
54. Emslie GJ, Findling R, Yeung P, et al. Venlafaxine XR in pediatric patients with major depressive disorder. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC; October 19-24, 2004.
55. Emslie GJ, Findling RL, Rynn M, et al. Efficacy and safety of nefazodone in the treatment of adolescents with major depressive disorder. Presented at the 42nd Annual Meeting of the NCDEU. Orlando, FL; June 10-13, 2002.
56. US Food and Drug Administration. Antidepressant use in children, adolescents and adults. Available at: http://www.fda.gov/cder/drugs/antidepressants. Accessed February 7, 2006.
57. Whittington C.J., Kendall T., Fonagy P., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 9418 (2004) 1341-1345
58. Emslie G.J., Mayes T.L., and Ruberu M. Continuation and maintenance therapy of early-onset major depressive disorder. Paediatr Drugs 7 4 (2005) 203-217
59. Emslie G.J., Rush A.J., Weinberg W.A., et al. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 7 1 (1998) 32-39
60. Keller M.B., Shapiro R.W., Lavori P.W., et al. Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry 39 8 (1982) 911-915
61. Emslie G.J., Heiligenstein J.H., Hoog S.L., et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43 11 (2004) 1397-1405
62. Greenhill L.L., Vitiello B., Fisher P., et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 43 12 (2004) 1488-1496
63. Vitiello B., Heiligenstein J.H., Riddle M.A., et al. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 56 1 (2004) 3-9
64. Weintrob N., Cohen D., Klipper-Aurbach Y., et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156 7 (2002) 696-701
65. Kandil S.T., Aksu H.B., and Ozyavuz R. Reversible nocturnal enuresis in children receiving SSRI with or without risperidone: presentation of five cases. Isr J Psychiatry Relat Sci 41 3 (2004) 218-221
66. Wilens T.E., Biederman J., Kwon A., et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 13 2 (2003) 143-152
67. Hammad T. Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed February 7, 2006.
68. Martin A., Young C., Leckman J.F., et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 158 8 (2004) 773-780
69. Baldessarini R.J., Faedda G.L., and Hennen J. Risk of mania with antidepressants. Arch Pediatr Adolesc Med 159 3 (2005) 298 [author reply: 298-9]
70. Licinio J., and Wong M.L. Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 4 2 (2005) 165-171
71. Kapur S., Mieczkowski T., and Mann J.J. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 268 24 (1992) 3441-3445
72. Khan A., Khan S., Kolts R., et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160 4 (2003) 790-792
73. Grunbaum J.A., Kann L., Kinchen S.A., et al. Youth risk behavior surveillance: United States, 2001. MMWR Surveill Summ 51 4 (2002) 1-62
74. Evans E., Hawton K., Rodham K., et al. The prevalence of suicidal phenomena in adolescents: a systematic review of population-based studies. Suicide Life Threat Behav 35 3 (2005) 239-250
75. Anderson R.N., and Smith B.L. Deaths: leading causes for 2001. Natl Vital Stat Rep 52 9 (2003) 1-85
76. Gould M.S., King R., Greenwald S., et al. Psychopathology associated with suicidal ideation and attempts among children and adolescents. J Am Acad Child Adolesc Psychiatry 37 9 (1998) 915-923
77. Fombonne E., Wostear G., Cooper V., et al. The Maudsley long-term follow-up of child and adolescent depression. II. Suicidality, criminality and social dysfunction in adulthood. Br J Psychiatry 179 (2001) 218-223
78. Marttunen M.J., Aro H.M., Henriksson M.M., et al. Mental disorders in adolescent suicide. DSM-III-R axes I and II diagnoses in suicides among 13- to 19-year-olds in Finland. Arch Gen Psychiatry 48 9 (1991) 834-839
79. Gould M.S., Greenberg T., Velting D.M., et al. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 42 4 (2003) 386-405
80. World Health Organization. Country reports and charts available. Available at: http://www.who.int/mental_health/prevention/suicide/country_reports/en/. Accessed February 7, 2006.
81. Olfson M., Shaffer D., Marcus S.C., et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60 10 (2003) 978-982
82. Valuck R.J., Libby A.M., Sills M.R., et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 18 15 (2004) 1119-1132
83. Leon A.C., Marzuk P.M., Tardiff K., et al. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 65 7 (2004) 915-918
84. Isacsson G., Holmgren P., and Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 111 4 (2005) 286-290
85. Moskos M., Olson L., Halbern S., et al. Utah youth suicide study: psychological autopsy. Suicide Life Threat Behav 35 5 (2005) 536-546
86. Olfson M, Marcus SC, Shaffer D. A case control study of antidepressants and suicide in severely depressed children and adults. Arch Gen Psychiatry, in press.
87. Simon G.E., Savarino J., Operskalski B., et al. Suicide risk during antidepressant treatment. Am J Psychiatry 163 1 (2006) 41-47
88. Gaspar P., Cases O., and Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 4 12 (2003) 1002-1012
89. Ansorge M.S., Zhou M., Lira A., et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306 5697 (2004) 879-881
90. Simon G.E., Cunningham M.L., and Davis R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159 12 (2002) 2055-2061
91. Moses-Kolko E.L., Bogen D., Perel J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293 19 (2005) 2372-2383
92. Zeskind P.S., and Stephens L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113 2 (2004) 368-375
93. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142 4 (2003) 402-408
94. Levinson-Castiel R., Merlob P., Linder N., et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160 2 (2006) 173-176
95. Borella A., Bindra M., and Whitaker-Azmitia P.M. Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies. Neuropharmacology 36 4-5 (1997) 445-450
96. Gross C., and Hen R. The developmental origins of anxiety. Nat Rev Neurosci 5 7 (2004) 545-552
97. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 4 3 (2002) 183-194
98. Mazer C., Muneyyirci J., Taheny K., et al. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 760 1-2 (1997) 68-73
99. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry, in press.
100. Asarnow J.R., Jaycox L.H., Duan N., et al. Effectiveness of a quality improvement intervention for adolescent depression in primary care clinics: a randomized controlled trial. JAMA 293 3 (2005) 311-319
101. Mufson L., Dorta K.P., Wickramaratne P., et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 61 6 (2004) 577-584
102. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37 10 Suppl (1998) 63S-83S
103. Clarke G., Debar L., Lynch F., et al. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry 44 9 (2005) 888-898